Spotlight On... Dengue vaccine developed at NIH enters PhIII in Brazil; Mucosis nets Wellcome Trust grant for intranasal RSV vax; Brazil commits to Zika research; and more...

A dengue fever vaccine developed by scientists at the National Institute of Allergy and Infectious Diseases is entering a Phase III trial in Brazil that may enroll nearly 17,000 people in 13 cities. The trial is expected to last 5 years, but investigators hope for early efficacy indications in less than two years. The São Paulo-based Butanatan Institute is sponsoring the trial and has licensed the vaccine technology, dubbed TV003. More

> Dutch vaccines firm Mucosis received a €3.7 million grant from Wellcome Trust to take its intranasal RSV vaccine to Phase I/IIa trials in conjunction with Imperial College London. Release

> Indian officials are working to set up a system that will track vaccine movement, usage and availability. News

> In the midst of the largest known Zika outbreak, the Brazilian government is committing funds to help develop a vaccine. Report

> Researchers are taking a vaccine targeting non-small cell lung cancer into an 812-patient Phase III trial. The work centers on a potential new biomarker that may help boost efficacy. Report

> Inovio Pharmaceuticals ($INO) netted a $500,000 Small Business Innovation Research grant from the U.S. Army to continue work on next-gen vaccine delivery. Release

And Finally… An Oxford University team is looking into using "bacterial superglue" to speed up the vaccine development process. News

Suggested Articles

Pfizer posted positive top-line results for a trial of its 20-valent pneumococcal vaccine, potentially setting up a filing by the end of 2020.

Univercells's new CDMO, Exothera, is hoping to play a role in helping drugmakers scale up manufacturing for a possible COVID-19 vaccine.

CanSino and its partners won a go-ahead to move a recombinant coronavirus vaccine into phase 1 testing in Wuhan, China, once the outbreak's center.